


**AMENDMENTS TO THE CLAIMS:**

Please amend claims 1, 22, 23, 28, and 29 as indicated below. Additions are underlined and deletions are in ~~strikethrough~~ font. This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A composition comprising:
  - a) at least one physiologically tolerated film-forming agent;
  - b) at least one physiologically tolerated solvent, wherein the solvent evaporates after application of the said composition to a skin surface;
  - c) at least one plasticizer, wherein the amount of plasticizer is from 0.05 percent by weight to 2.5 percent by weight; and
  - d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R<sup>1</sup> is
- 1) -CN,
  - 2) -NO<sub>2</sub>,
  - 3) a halogen, or
  - 4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;
- R<sup>2</sup> is
- 1) -CF<sub>3</sub>,
  - 2) a halogen, or

3) -CN;

R<sup>3</sup> is 1) =O,

2) =S, or


3) =NH;

X is 1) a radical of formula II




or

2) a radical of formula III



or X and Y together form a group of formula IV



in which R<sup>4</sup> is 1) hydrogen atom,

2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or

4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-, wherein the alkyl is mono- to trisubstituted by

4.1 -OH,


4.2 halogens,

4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

4.4 -CN, or

4.5 -SH;


Y is 1) a radical of formula V



in which:

$\text{R}^5$  is, independently of  $\text{R}^6$ , a hydrogen atom or  $(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and  $\text{R}^6$  is, independently of  $\text{R}^5$ ,  $(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by


- a) halogens,
  - b) phenyl- $(\text{CH}_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by  $-\text{COOH}$ ,  $-\text{CN}$ , or  $-\text{CF}_3$ , and  $m$  is the integer zero, 1, 2, 3, 4, 5, or 6,
  - c)  $-\text{COOH}$ ,
  - d)  $-\text{CN}$ , or
  - e)  $-\text{CF}_3$ , or
- 2) radical of formula VI,



in which  $\text{R}^4$  is as defined above; and

Z is 1)  $-\text{O}-$  or

2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

2. (Original) A composition as claimed in claim 1, wherein the compound of formula I is a compound in which:

- R<sup>1</sup> is 1) -CN,  
2) -NO<sub>2</sub>, or  
3) a halogen;

- R<sup>2</sup> is 1) -CF<sub>3</sub> or  
2) a halogen;

- R<sup>3</sup> is 1) =O or  
2) =S;

X is the radical of formula II or III, or

X and Y together form the group of formula IV,

in which R<sup>4</sup> is as defined in claim 1;

Y is the radical of formula VI,

in which R<sup>4</sup> is as defined in claim 1; and

Z is the radical of formula VII.

3. (Withdrawn) A composition as claimed in claim 1, wherein the compound of formula I is a compound in which:

R<sup>1</sup> is -CN;

R<sup>2</sup> is -CF<sub>3</sub>;

$R^3$  is  $=0$ ;

X is the radical of formula II;

Y is the radical of formula VI, in which  $R^4$  is hydrogen; and

Z is  $-O-$  or the radical of formula VII.

4. (Original) A composition as claimed in claim 1, wherein the compound of formula I is chosen from 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile and 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2-(trifluoromethyl)-benzonitrile.

5. (Original) A composition as claimed in claim 1, wherein the at least one plasticizer is chosen from ethoxylated compounds, panthenol, esters of adipic acid, and esters of sebacic acid.

6. (Original) A composition as claimed in claim 5, wherein the at least one plasticizer is chosen from polyoxyethylated castor oil, ethoxylated cholesterol, and panthenol.

7. (Original) A composition as claimed in claim 1, wherein the at least one physiologically tolerated solvent is chosen from water and  $(C_1-C_6)$ -alcohols.

8. (Original) A composition as claimed in claim 7, wherein the (C<sub>1</sub>-C<sub>6</sub>)-alcohols are chosen from methanol, ethanol, propanol, isopropanol, butanol, pentanol, and hexanol.

9. (Withdrawn) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one naturally occurring substance chosen from alginic acid, alginates, collagen, collagen derivatives, hydrolyzed wheat proteins, carrageenan, cellulose, cellulose derivatives, chitosan, chitosan derivatives, keratin hydrolysates, protein hydrolysates, gelatin, guar gum, guar gum derivatives, hydrolyzed elastin, hydrolyzed milk proteins, hydrolyzed silk proteins, hydrolyzed soya proteins, hydrolyzed oat proteins, copolymers of hydroxyethylcellulose, dimethyldiallylammonium chloride, hyaluronic acid, hyaluronates, tragacanth, and xanthan.

10. (Previously Presented) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from acrylate copolymers, methacrylic acid copolymers, adipic acid/dimethyl-aminohydroxypropyldiethylenetriamine copolymers, polysiloxanes, ethylene/vinyl acetate copolymers, poly(methyl vinyl ether-maleic anhydride), poly(vinylpyrrolidone), polyvinylpyrrolidone/eicosene copolymers, and polyvinylpyrrolidone/hexadecene copolymers.

11. (Original) A composition as claimed in claim 1, further comprising at least one additive chosen from circulation-promoting compounds, angiotensin converting enzyme inhibitors, methylxanthine compounds, sodium channel openers, and hair growth-promoting compounds.

12. (Original) A composition as claimed in claim 11, wherein at least one circulation-promoting compound is chosen from dihydralazine, diisopropylamine, diazoxide, and calcium antagonists.

13. (Original) A composition as claimed in claim 12, wherein at least one calcium antagonist is chosen from nifedipine, nicardipine, verapamil, diltiazem, nisoldipine, nitrendipine, nivaldipine, isradipine, felodipine, nimodipine, gallopamil, fendiline, flunarizine, amlodipine, doperdipine, fluspirilene, primozide, fantofarone, nicergoline, cyclandelate, and 6-amino-4-piperidino-1,2-dihydro-1-hydroxy-2-iminopyrimidine.

14. (Original) A composition as claimed in claim 11, wherein at least one angiotensin converting enzyme inhibitor is chosen from quinapril, lisinopril, benzazepril, captopril, ramipril, fosinopril, cifazapril, and tradolapril.

15. (Original) A composition as claimed in claim 11, wherein at least one methylxanthine compound is chosen from pentoxifyllin, propentofyllin, and torbafyllin.

16. (Original) A composition as claimed in claim 11, wherein at least one sodium channel opener is chosen from 1-cyano-2-(1,1-dimethyl-propyl)-3-(3-pyridyl)guanidine and 5-alpha-reductase inhibitors.

17. (Original) A composition as claimed in claim 16, wherein at least one 5-alpha-reductase inhibitor is N-tert-butyl-3-oxo-4aza-5 $\alpha$ -androst-1-ene-17 $\beta$ -carboxamide.

18. (Original) A composition as claimed in claim 11, wherein at least one hair growth-promoting compound is chosen from inner salts of 2,4-diamino-6-alkoxy-3-sulfoxypyrimidine hydroxide having from 1 to 6 carbon atoms in the alkoxy radical, pyridine 1-oxide compounds, and 2,6-diamino-1,3,5-triazine compounds.

19. (Original) A composition as claimed in claim 18, wherein at least one hair growth-promoting compound is an inner salt of 2,4-diamino-6-butoxy-3-sulfoxypyrimidine hydroxide.


20. (Original) A composition as claimed in claim 18, wherein at least one pyridine 1-oxide compound is 2,6-diamino-4-piperidinopyridine.

21. (Original) A composition as claimed in claim 18, wherein at least one 2,6-diamino-1,3,5-triazine compound is 2,6-diamino-4-butoxy-1,3,5-triazine 1-oxide.



22. (Currently Amended) A process for making a composition, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent, wherein the solvent evaporates after application of the said composition to a skin surface;
- c) at least one plasticizer, wherein the amount of plasticizer is from 0.05 percent by weight to 2.5 percent by weight; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- $R^1$  is
- 1)  $-\text{CN}$ ,
  - 2)  $-\text{NO}_2$ ,
  - 3) a halogen, or
  - 4)  $(\text{C}_1\text{-C}_4)\text{-alkyl-C(O)-OH}$ ;

- $R^2$  is
- 1)  $-\text{CF}_3$ ,
  - 2) a halogen, or
  - 3)  $-\text{CN}$ ;


- $R^3$  is
- 1)  $=\text{O}$ ,
  - 2)  $=\text{S}$ , or
  - 3)  $=\text{NH}$ ;

X is 1) a radical of formula II




or

2) a radical of formula III



or X and Y together form a group of formula IV



in which R<sup>4</sup> is 1) hydrogen atom,

2) (C1-C6)-alkyl-,

3) (C2-C6)-alkenyl-, or

4) (C1-C6)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

4.1 -OH,


4.2 halogens,

4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

4.4 -CN, or

4.5 -SH;


Y is 1) a radical of formula V



in which:


$R^5$  is, independently of  $R^6$ , a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and  $R^6$  is, independently of  $R^5$ , (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
  - b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
  - c) -COOH,
  - d) -CN, or
  - e) -CF<sub>3</sub>, or
- 2) a radical of formula VI,



in which  $R^4$  is as defined above; and


- Z is
- 1) -O- or
  - 2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

23. (Currently Amended) A process for the treatment of androgenic alopecia, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent, wherein the solvent evaporates after application of the said composition to a skin surface;
- c) at least one plasticizer, wherein the amount of plasticizer is from 0.05 percent by weight to 2.5 percent by weight; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- |                   |   |
|-------------------|---|
| R <sup>1</sup> is | 1) -CN,   |
|                   | 2) -NO <sub>2</sub> ,                               |
|                   | 3) a halogen, or                                    |
|                   | 4) (C <sub>1</sub> -C <sub>4</sub> )-alkyl-C(O)-OH; |
| R <sup>2</sup> is | 1) -CF <sub>3</sub> ,                               |
|                   | 2) a halogen, or                                    |
|                   | 3) -CN;   |
| R <sup>3</sup> is | 1) =O,  |

2) =S, or


3) =NH;

X is 1) a radical of formula II




or

2) a radical of formula III




or X and Y together form a group of formula IV



in which R<sup>4</sup> is

- 1) hydrogen atom,
- 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
- 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
- 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-, wherein the alkyl is mono- to trisubstituted by
  - 4.1 -OH,
  - 4.2 halogens,
  - 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
  - 4.4 -CN, or
  - 4.5 -SH;


Y is 1) a radical of formula V



in which:


$\text{R}^5$  is, independently of  $\text{R}^6$ , a hydrogen atom or  $(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and  $\text{R}^6$  is, independently of  $\text{R}^5$ ,  $(\text{C}_1\text{-C}_4)$ -alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
  - b) phenyl- $(\text{CH}_2)_m$ -, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by  $-\text{COOH}$ ,  $-\text{CN}$ , or  $-\text{CF}_3$ , and  $m$  is the integer zero, 1, 2, 3, 4, 5, or 6,
  - c)  $-\text{COOH}$ ,
  - d)  $-\text{CN}$ , or
  - e)  $-\text{CF}_3$ , or
- 2) radical of formula VI,



in which  $\text{R}^4$  is as defined above; and

- Z is
- 1)  $-\text{O}-$  or
  - 2) a radical of formula VII




wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

24-27. (Canceled)

28. (Currently Amended) A process for treatment of seborrhea or acne, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent, wherein the solvent evaporates after application of the said composition to a skin surface;
- c) at least one plasticizer, wherein the amount of plasticizer is from 0.05 percent by weight to 2.5 percent by weight; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R<sup>1</sup> is
- 1) -CN,
  - 2) -NO<sub>2</sub>,
  - 3) a halogen, or

4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;

R<sup>2</sup> is 1) -CF<sub>3</sub>,

2) a halogen, or

3) -CN;

R<sup>3</sup> is 1) =O,

2) =S, or


3) =NH;

X is 1) a radical of formula II




or

2) a radical of formula III



or X and Y together form a group of formula IV



in which R<sup>4</sup> is 1) hydrogen atom,

2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or

4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-, wherein the alkyl is mono- to trisubstituted by

4.1 -OH,




4.2 halogens,

4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,

4.4 -CN, or

4.5 -SH;

Y is 1) a radical of formula V




in which:

R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by


- a) halogens,
- b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF<sub>3</sub>, or

2) radical of formula VI,




in which  $R^4$  is as defined above; and

- Z is 1) -O- or  
2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

29. (Currently Amended) A cosmetic composition comprising:
- a) at least one physiologically tolerated film-forming agent;
  - b) at least one physiologically tolerated solvent, wherein the solvent evaporates after application of the said composition to a skin surface;
  - c) at least one plasticizer, wherein the amount of plasticizer is from 0.05 percent by weight to 2.5 percent by weight; and
  - d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- $R^1$  is 1) -CN,  
2) -NO<sub>2</sub>,

- 3) a halogen, or
- 4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;

- R<sup>2</sup> is
- 1) -CF<sub>3</sub>,
  - 2) a halogen, or
  - 3) -CN;


- R<sup>3</sup> is
- 1) =O,
  - 2) =S, or
  - 3) =NH;

- X is
- 1) a radical of formula II




or

- 2) a radical of formula III




or X and Y together form a group of formula IV



- in which R<sup>4</sup> is
- 1) hydrogen atom,
  - 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
  - 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
  - 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-, wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V




in which:

R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to tetrasubstituted by halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
- c) -COOH,
- d) -CN, or
- e) -CF<sub>3</sub>, or


- 2) a radical of formula VI,



in which R<sup>4</sup> is as defined above; and

Z is 1) -O- or

- 2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

30-38. (Canceled)

39. (Previously Presented) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from acrylate/acrylamide copolymers, methacrylic acid/methacrylic acid ester copolymers neutralized with 2-amino-2-methylpropanol, polysiloxane/polyalkyl polyether copolymers, ethylene/acrylic acid ester copolymers, polyvinylpyrrolidone/imidazolinium methochloride copolymers, sodium acrylate/dimethyldiallylammonium chloride copolymers, poly(methyl vinyl ether-maleic acid monoalkyl ester), and poly(vinylpyrrolidone-dimethylaminoethylmethacrylic acid).

40. (Previously Presented) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from acrylate/octylacrylamide copolymers, quaternized polyvinylpyrrolidone-dimethylaminoethylmethacrylic acid esters, poly(dimethylsiloxane-copolyol-phospho-panthenoate), and vinylimidazolium methochloride/vinylpyrrolidone copolymers.

41. (Withdrawn) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from acrylic acid ester copolymers, and polyvinylpyrrolidone/methacrylic acid ester/methacrylic acid terpolymers.

42. (Withdrawn) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from polyacrylic acid crosslinked with pentaerythritol ethers or sugar allyl ethers, terpolymers based on pyrrolidone and acrylic acid compounds, and polyvinylpyrrolidone/vinyl acetate copolymers.

43. (Withdrawn) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from polyvinylpyrrolidone/polycarbamyl polyglycol ester, and acrylic acid/acrylic acid ester copolymers.

44. (Withdrawn) A composition as claimed in claim 1, wherein the at least one physiologically tolerated film-forming agent comprises at least one synthetic substance chosen from methacryloylethylbetaine/methacrylic acid copolymers, dimethyldiallylammonium chloride/sodium acrylate/acrylamide terpolymers, octylacrylamide/acrylic acid ester/butylaminoethylmethacrylic acid copolymers, and terpolymers of vinyl pyrrolidone, vinyl acetate, and vinyl propionate.